文献速递脑血管病

阴道雌二醇与既往缺血性卒中女性复发性缺血性卒中:全国嵌套病例对照研究

Recurrent Ischemic Stroke and Vaginal Estradiol in Women With Prior Ischemic Stroke: A Nationwide Nested Case-Control Study.
PubMed 文献 · Stroke · 2025-08-21

本研究基于全国登记数据,纳入2008至2017年间首次缺血性卒中且卒中前无阴道雌激素使用史的≥45岁女性,采用嵌套病例对照设计,按出生年份1:1匹配复发性缺血性卒中病例与对照。调整合并症、用药、收入和教育后,阴道雌二醇片使用与复发性缺血性卒中率升高无关。

要点

  • 阴道雌二醇片使用与复发性缺血性卒中风险增加无关。
  • 当前使用调整后HR为0.79(95%CI 0.52-1.20),差异无统计学意义。
  • 既往使用调整后HR为1.48(95%CI 0.95-2.30),差异无统计学意义。

核心结论

  • 在有缺血性卒中史的女性中,使用阴道雌二醇片与复发性缺血性卒中率升高无关。

研究设计与样本

  • 全国嵌套病例对照研究,纳入2008年1月1日至2017年12月31日期间发生首次缺血性卒中且卒中前无阴道雌激素使用史的≥45岁女性。
  • 中位年龄75岁(SD,12)。

主要发现

  • 调整合并症、用药、收入和教育后,当前使用阴道雌二醇片的调整后风险比为0.79(95%CI,0.52-1.20;P=0.27)。
  • 近期使用的调整后风险比为1.09(95%CI,0.73-1.63;P=0.67)。
  • 既往使用的调整后风险比为1.48(95%CI,0.95-2.30;P=0.08)。

关键数值与推荐

  • 当前使用定义为索引日期前0-3个月;近期使用为索引日期前3-24个月;既往使用为索引日期前>24个月。
  • 索引日期定义为复发性缺血性卒中诊断日期。

临床怎么用

  • 对于有缺血性卒中史的女性,阴道雌二醇片使用可能不会增加复发性缺血性卒中风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic estrogen replacement therapy is contraindicated in women with a history of ischemic stroke due to the risk of stroke recurrence. There are currently no published data available describing the association between vaginal estrogen use and recurrent ischemic stroke in women with a history of ischemic stroke. This study aimed to examine the association between vaginal estradiol tablet use and the rate of recurrent ischemic stroke in women with a history of ischemic stroke. METHODS: Using nationwide registers, we conducted a nationwide nested case-control study including all women aged ≥45 years who developed a first ischemic stroke between January 1, 2008, and December 31, 2017, with no history of vaginal estrogen use before stroke diagnosis. Using incidence density sampling, we matched cases with recurrent ischemic stroke 1:1 to controls based on birth year. The index date was defined as the date of recurrent ischemic stroke diagnosis. Exposure to vaginal estradiol tablets was assessed using prescription data and categorized as current use (0-3 months before index), recent use (3-24 months before index), and past use (>24 months before index). RESULTS: From a cohort of 56 642 women with a first-time stroke, we identified 3353 recurrent cases, which were matched by birth year with 3353 controls. The median age was 75 (SD, 12) years. When adjusted for comorbidity, medications, income, and education, exposure to vaginal estradiol tablets was not associated with an increased rate of recurrent ischemic stroke (current use: adjusted hazard ratio, 0.79 [95% CI, 0.52-1.20]; P=0.27; recent use: adjusted hazard ratio, 1.09 [95% CI, 0.73-1.63]; P=0.67; and past use: adjusted hazard ratio, 1.48 [95% CI, 0.95-2.30]; P=0.08). CONCLUSIONS: In this nested case-control study, use of vaginal estradiol tablets was not associated with an increased rate of recurrent ischemic stroke in women with a history of ischemic stroke. Based on our findings, vaginal estradiol tablets are not likely to increase the risk of recurrent ischemic stroke in women with prior stroke.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Haddadan KG, Eckert-Lind C, Meaidi A, et al. Recurrent Ischemic Stroke and Vaginal Estradiol in Women With Prior Ischemic Stroke: A Nationwide Nested Case-Control Study. Stroke. 2025. PMID: 40836911. doi:10.1161/STROKEAHA.125.050986

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。